<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Radiat Oncol</journal-id><journal-id journal-id-type="iso-abbrev">Radiat Oncol</journal-id><journal-title-group><journal-title>Radiation Oncology (London, England)</journal-title></journal-title-group><issn pub-type="epub">1748-717X</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27464793</article-id><article-id pub-id-type="pmc">4963927</article-id><article-id pub-id-type="publisher-id">675</article-id><article-id pub-id-type="doi">10.1186/s13014-016-0675-x</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Resistance training concomitant to radiotherapy of spinal bone metastases &#x02013; survival and prognostic factors of a randomized trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3610-973X</contrib-id><name><surname>Rief</surname><given-names>Harald</given-names></name><address><phone>49-6221-56-8202</phone><email>harald.rief@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>Bruckner</surname><given-names>Thomas</given-names></name><address><email>bruckner@imbi.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Schlampp</surname><given-names>Ingmar</given-names></name><address><email>ingmar.schlampp@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bostel</surname><given-names>Tilman</given-names></name><address><email>tilmann.bostel@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Welzel</surname><given-names>Thomas</given-names></name><address><email>thomas.welzel@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Debus</surname><given-names>J&#x000fc;rgen</given-names></name><address><email>juergen.debus@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author"><name><surname>F&#x000f6;rster</surname><given-names>Robert</given-names></name><address><email>robert.foerster@med.uni-heidelberg.de</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label>Department of Radiation Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 400, 69120 Heidelberg, Germany </aff><aff id="Aff2"><label>2</label>Department of Medical Biometry, University Hospital Heidelberg, Im Neuenheimer Feld 305, 69120 Heidelberg, Germany </aff><aff id="Aff3"><label>3</label>National Center for Radiation Oncology (NCRO), Heidelberg Institute for Radiation Oncology (HIRO), Im Neuenheimer Feld 400, 69120 Heidelberg, Germany </aff></contrib-group><pub-date pub-type="epub"><day>27</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>27</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>11</volume><elocation-id>97</elocation-id><history><date date-type="received"><day>8</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>22</day><month>7</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s). 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Purpose</title><p>To compare the effects of resistance training versus passive physical therapy on bone survival in the metastatic bone during radiation therapy (RT) as combined treatment in patients with spinal bone metastases. Secondly, to evaluate overall survival and progression-free-survival (PFS) as well as to quantify prognostic factors of bone survival after combined treatment.</p></sec><sec><title>Methods</title><p>In this randomized trial 60 patients were allocated from September 2011 until March 2013 into one of the two groups: resistance training (group A) or passive physical therapy (group B) with thirty patients in each group during RT. We estimated patient survival using Kaplan-Meier survival method. The Wald-test was used to evaluate the prognostic importance of pathological fracture, primary site, Karnofsky performance status, localization of metastases, number of metastases, and cerebral metastases.</p></sec><sec><title>Results</title><p>Median follow-up was 10&#x000a0;months (range 2&#x02013;35). Bone survival showed no significant difference between groups (<italic>p</italic> = .303). Additionally no difference between groups could be detected in overall survival (<italic>p</italic> = .688) and PFS (<italic>p</italic> = .295). Local bone progression was detected in 16.7&#x000a0;% in group B, no irradiated bone in group A showed a local progression over the course (<italic>p</italic> = 0.019). In univariate analysis breast cancer, prostate cancer, and the presence of cerebral metastases had a significant impact on bone survival in group B, while no impact could be demonstrated in group A.</p></sec><sec><title>Conclusions</title><p>In this group of patients with spinal bone metastases we were able to show that guided resistance training of the paravertebral muscles had no essential impact on survival concomitant to RT. Importantly, no local bone progression in group A was detected, nevertheless no prognostic factor for combined treatment could be evaluated.</p></sec><sec><title>Trial registration</title><p>Clinical trial identifier <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01409720">NCT 01409720</ext-link>. Registered 8 February 2011.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Bone metastases</kwd><kwd>Spine</kwd><kwd>Resistance training</kwd><kwd>Survival</kwd><kwd>Palliative radiotherapy</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Spinal bone metastases represent the most frequent site of skeletal metastasis [<xref ref-type="bibr" rid="CR1">1</xref>], and two-thirds of all tumor patients are estimated to develop bone metastases in the course of their disease [<xref ref-type="bibr" rid="CR2">2</xref>]. Bone metastases are a major clinical concern due to severe pain, pathological fractures, spinal cord compression and hypercalcaemia with a significant decrease of the quality of life (QoL) [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. Radiotherapy (RT) is the most common treatment option of bone metastases in advanced tumor disease [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR6">6</xref>], and is effective in reducing symptoms, increases subjective well-being, and has minimal side effects [<xref ref-type="bibr" rid="CR7">7</xref>]. The classification into stable and unstable bone metastases and pathological fractures are of great clinical relevance regarding mobility and QoL in patients&#x02019; palliative care. Most patients with spinal metastases have a limited life expectancy [<xref ref-type="bibr" rid="CR8">8</xref>]. The early initiation of therapy, which can generally be viewed as being given as palliative therapy, brings about a significant improvement of the QoL and appears to prolong the survival time [<xref ref-type="bibr" rid="CR9">9</xref>]. The median overall survival varies from 7 to 32&#x000a0;months, depending on significant predictors e.g., Karnofsky performance score (KPS), primary tumor, and the absence of visceral metastases [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>&#x02013;<xref ref-type="bibr" rid="CR12">12</xref>]. Previously we showed that within our study guided resistance training of the paravertebral muscles could safety be practiced in palliative patients with stable bone metastases of the vertebral column; leading to an improved pain score and mobility as well as reduced fatigue and thereby an enhanced QoL [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Secondary, we were able to show that resistance training concomitant to RT can improve pain relief, and improve bone density in the metastasis as a local response over a 6-months period [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. However, in our recent work, we analyzed the endpoints feasibility, QoL, local response, and pain of resistance training in patients with spinal bone metastases under RT until 6&#x000a0;months. The aim of this analysis was to compare the bone survival of patients with spinal bone metastases under resistance training versus passive physical therapy concomitant to RT. Secondary endpoints were overall survival, progression free survival, and to quantify prognostic factors to bone survival after combined treatment.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><p>This is a randomized, controlled, two-armed intervention trial. A block randomization approach with block size 6 was used to ensure that the two groups were balanced. Inclusion criteria were an age of 18 to 80&#x000a0;years, KPS [<xref ref-type="bibr" rid="CR17">17</xref>]&#x02009;&#x02265;&#x02009;70, written consent to participate, and already initiated bisphosphonate therapy. The patients were subjected to a staging of their vertebral column within the context of the computed tomography (CT) designed to plan the radiation schedule prior to enrolment into the trial. In this examination metastases were classified as &#x0201c;stable&#x0201d; or &#x0201c;unstable&#x0201d;. This was diagnosed independently by a specialist for radiology as well as by a specialist for orthopedic surgery. The specifications for an unstable vertebral body were tumor occupancy more than 60&#x000a0;% of the vertebral body, and pedicle destruction [<xref ref-type="bibr" rid="CR18">18</xref>]. Only a metastasis classified by both specialists as &#x0201c;stable&#x0201d; was suggested eligible for inclusion. After the baseline measurements, the patients with stable bone metastases were assigned to the respective treatment groups on a 1:1 basis according to the randomization list. Group A (intervention group, resistance training) and in group B (control group, passive physical therapy) each consisted of 30 patients. The primary endpoint was to compare bone survival between the two groups. Secondary endpoints were to quantify overall survival, progression free survival (PFS), and prognostic factors for bone survival. Local bone progression was defined as progressive treated bone metastasis, while systemic progressive bone was defined as additional bone metastases to the treated site. Progressive disease was defined as local progression and/or systemic progressive bone and/or death. PFS was the time between first diagnosis or existence of bone metastases (time equalized to the start of RT) until progressive disease or death. The progression of bone disease was estimated by CT scans 3, 6, 12 and 24&#x000a0;months after RT. The progressive treated bone metastases were classified by MDA criteria [<xref ref-type="bibr" rid="CR19">19</xref>]. Bone survival was the time from first diagnosis or existence of bone metastases (time equalized to the start of RT) until death, and overall survival was the time from first diagnosis of primary site until death. Bone metastases distant from the irradiated site were not included. Patient-specific data was documented. The study was approved by the Heidelberg Ethics Committee (S-316/2011).</p><sec id="Sec3"><title>Radiotherapy</title><p>Radiotherapy was performed in the Department of Radiation Oncology at the University Hospital Heidelberg. After virtual simulation was performed for treatment planning, radiotherapy was carried out over a dorsal photon field of 6MV energy range. Primary target volume (PTV) covered the specific vertebral body affected as well as the ones immediately above and below. In group A twenty-four patients (80&#x000a0;%) were treated with 10 &#x000d7; 3&#x000a0;Gy, three patients (10&#x000a0;%) with 14 &#x000d7; 2.5&#x000a0;Gy, and three patients (10&#x000a0;%) with 20 &#x000d7; 2&#x000a0;Gy. In group B the dose fractions for twenty-eight patients (93.3&#x000a0;%) were 10 &#x000d7; 3&#x000a0;Gy, for one patient (3.3&#x000a0;%) 14 &#x000d7; 2.5&#x000a0;Gy, and for one patient (3.3&#x000a0;%) 20 &#x000d7; 2&#x000a0;Gy. The median individual dose in all patients was 3&#x000a0;Gy (range 2&#x02013;3&#x000a0;Gy), the median total dose 30&#x000a0;Gy (range 20&#x02013;35&#x000a0;Gy). The individual and total doses were decided separately for each individual patient, depending on histology, patient&#x02019;s general state of health, current staging and the corresponding prognosis.</p></sec><sec id="Sec4"><title>Exercise interventions</title><p>The interventions commenced on the same day as radiotherapy and were performed on each day of RT treatment (Monday through Friday) over a 2-week period, independent of the number of fractions. During the 2-week RT period, the patients in the resistance training group (group A) performed the exercises under the guidance of a trained physiotherapist. The patients were then instructed to perform all trainings at home three times per week until the endpoint assessment after 6 months. Self-reported training adherence was registered in a training diary. The resistance training lasted approx. 30&#x000a0;min, the passive physical therapy (group B) approx. 15&#x000a0;min. Since the site of the bone metastases differed from patient to patient, three different exercises were enacted to ensure an even resistance training of the muscles along the entire vertebral column. A detailed description of the exercise interventions was published earlier [<xref ref-type="bibr" rid="CR16">16</xref>, <xref ref-type="bibr" rid="CR20">20</xref>].</p></sec><sec id="Sec5"><title>Statistical approach</title><p>On account of the explorative character of this study it was not possible to estimate the total number of cases; with a scheduled number of 30 patients per group, it will, however, be possible to detect a standardized mean-value effect of 0.74 with a power of 80&#x000a0;% and an &#x003b1; significance level of 5&#x000a0;%. We calculated descriptive <italic>p</italic>-values of the corresponding statistical tests comparing the treatment groups. Wilcoxon <italic>u</italic> test was used for difference between groups. We estimated patient survival using Kaplan-Meier survival method. Patients were censored on the basis of whether they were alive. The Wald-test was used to evaluate the prognostic importance of pathological fracture (yes/no), primary site (non-small cell lung cancer (NSCLC), breast cancer, prostate cancer, other), KPS (70/&#x0003e;70), localization of metastases (thoracic/lumbar), number of metastases (1/&#x0003e;1), and cerebral metastases. The results were reported as survival times, <italic>p</italic>-values, hazard ratios including 95&#x000a0;% confidence intervals (CI). For all analysis, a <italic>p</italic>-value of 0.05 or less was considered significant. All statistical analyses were done using SAS software Version 9.3 (SAS Institute, Cary, NC, USA).</p></sec></sec><sec id="Sec6" sec-type="results"><title>Results</title><p>From September 2011 through March 2013, consecutively 80 patients with a histologically confirmed cancer of any primary and spinal bone metastases of the thoracic or lumbar segments were considered in the Department of Radiation Oncology at the University Hospital Heidelberg. Fifteen patients were excluded due to unstable metastases, and five patients declined to participate in the study. Sixty patients fulfilled the inclusion criteria and were enrolled into the trial. Groups were balanced at baseline, and except for visceral metastases there were no group differences (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>). The median follow-up was 10&#x000a0;months (range 2&#x02013;35) for both groups. All surviving patients completed all surveys. Mortality did not differ between groups.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Patient characteristics at baseline</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">Intervention group A (<italic>n</italic>&#x02009;=&#x02009;30)</th><th colspan="2">Control group B (<italic>n</italic>&#x02009;=&#x02009;30)</th><th>
<italic>P</italic>-value</th></tr><tr><th>
<italic>n</italic>
</th><th>%</th><th>n</th><th>%</th><th/></tr></thead><tbody><tr><td colspan="6">Age (years)</td></tr><tr><td>&#x02003;Mean (SD)</td><td>61.3 +/- 10.1</td><td/><td>64.1 +/- 10.9</td><td/><td>0.304</td></tr><tr><td colspan="6">Gender</td></tr><tr><td>&#x02003;Male</td><td>14</td><td>46.7</td><td>19</td><td>63.3</td><td>0.195</td></tr><tr><td>&#x02003;Female</td><td>16</td><td>53.3</td><td>11</td><td>36.7</td><td/></tr><tr><td>Karnofsky-index (median, range)</td><td>80 (70&#x02013;100)</td><td/><td>80 (70&#x02013;100)</td><td/><td>0.114</td></tr><tr><td colspan="6">Primary site</td></tr><tr><td>&#x02003;Lung cancer</td><td>12</td><td>40.0</td><td>8</td><td>26.6</td><td>0.320</td></tr><tr><td>&#x02003;Breast cancer</td><td>5</td><td>16.7</td><td>6</td><td>20.0</td><td>0.542</td></tr><tr><td>&#x02003;Prostate cancer</td><td>5</td><td>16.7</td><td>9</td><td>30.0</td><td>0.156</td></tr><tr><td>&#x02003;Melanoma</td><td>1</td><td>3.3</td><td>1</td><td>3.3</td><td>1.000</td></tr><tr><td>&#x02003;Renal cancer</td><td>1</td><td>3.3</td><td>2</td><td>6.7</td><td>0.875</td></tr><tr><td>&#x02003;Other</td><td>6</td><td>20.0</td><td>4</td><td>13.4</td><td>0.325</td></tr><tr><td>Localization metastases</td><td/><td/><td/><td/><td>0.717</td></tr><tr><td>&#x02003;Thoracic</td><td>17</td><td>56.7</td><td>14</td><td>46.7</td><td/></tr><tr><td>&#x02003;Lumbar</td><td>9</td><td>30.0</td><td>13</td><td>43.3</td><td/></tr><tr><td>&#x02003;Thoracic and lumbar</td><td>2</td><td>6.7</td><td>2</td><td>6.7</td><td/></tr><tr><td>&#x02003;Sacrum</td><td>2</td><td>6.7</td><td>1</td><td>3.3</td><td/></tr><tr><td>Number metastases</td><td/><td/><td/><td/><td>0.257</td></tr><tr><td>&#x02003;Mean (range)</td><td>1.4 (2&#x02013;4)</td><td/><td>1.7 (1&#x02013;5)</td><td/><td/></tr><tr><td>&#x02003;Solitary</td><td>22</td><td>73.3</td><td>18</td><td>60.0</td><td/></tr><tr><td>&#x02003;Multiple</td><td>8</td><td>26.7</td><td>12</td><td>40.0</td><td/></tr><tr><td>Type of metastases</td><td/><td/><td/><td/><td>0.781</td></tr><tr><td>&#x02003;osteoblast</td><td>9</td><td>30.0</td><td>10</td><td>33.3</td><td>0.956</td></tr><tr><td>&#x02003;osteolytic</td><td>21</td><td>70.0</td><td>20</td><td>66.7</td><td>0.935</td></tr><tr><td>Distant metastases at baseline</td><td/><td/><td/><td/><td/></tr><tr><td>&#x02003;Visceral</td><td>12</td><td>40.0</td><td>5</td><td>16.7</td><td>0.045</td></tr><tr><td>&#x02003;brain</td><td>3</td><td>10.0</td><td>4</td><td>13.4</td><td>0.688</td></tr><tr><td>&#x02003;lung</td><td>7</td><td>23.3</td><td>4</td><td>13.4</td><td>0.320</td></tr><tr><td>&#x02003;tissue</td><td>8</td><td>26.7</td><td>6</td><td>20.0</td><td>0.542</td></tr><tr><td>Pathological fractures</td><td>6</td><td>20.0</td><td>9</td><td>30.0</td><td>0.371</td></tr><tr><td>Hormonotherapy</td><td>10</td><td>33.3</td><td>16</td><td>53.3</td><td>0.118</td></tr><tr><td>Immunotherapy</td><td>7</td><td>23.3</td><td>5</td><td>16.7</td><td>0.519</td></tr><tr><td>Chemotherapy</td><td>25</td><td>83.3</td><td>20</td><td>66.7</td><td>0.136</td></tr><tr><td>Neurological deficit</td><td>0</td><td>0.0</td><td>2</td><td>6.7</td><td>0.150</td></tr><tr><td>Orthopedic corset at baseline</td><td>7</td><td>23.3</td><td>5</td><td>16.7</td><td>0.519</td></tr><tr><td colspan="6">Radiotherapy dose completed (Gy)</td></tr><tr><td>single dose (median, range)</td><td>3 (2&#x02013;4)</td><td/><td>3 (2&#x02013;4)</td><td/><td>1.000</td></tr><tr><td>cumulative dose (median, range)</td><td>30 (30&#x02013;40)</td><td/><td>30 (30&#x02013;40)</td><td/><td>1.000</td></tr></tbody></table></table-wrap></p><p>Bone survival showed no significant difference between groups (<italic>p </italic>= 0.303); bone survival after 12 and 24&#x000a0;months was 58 and 42&#x000a0;% in group A, and 51 and 30&#x000a0;% in group B (Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>). Overall survival after 12 and 24&#x000a0;months was 80 and 63&#x000a0;% in group A, and 70 and 57&#x000a0;% in group B respectively (<italic>p</italic>=0.688; Fig.&#x000a0;<xref rid="Fig2" ref-type="fig">2</xref>). The PFS did not differ between groups; mean PFS was 24.3&#x000a0;months in group A and 20.5&#x000a0;months in group B (<italic>p</italic> = 0.295; Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Progression free survival of both groups</p></caption><graphic xlink:href="13014_2016_675_Fig1_HTML" id="MO1"/></fig><fig id="Fig2"><label>Fig. 2</label><caption><p>Overall survival of both groups</p></caption><graphic xlink:href="13014_2016_675_Fig2_HTML" id="MO2"/></fig><fig id="Fig3"><label>Fig. 3</label><caption><p>Bone survival of both groups</p></caption><graphic xlink:href="13014_2016_675_Fig3_HTML" id="MO3"/></fig></p><p>Local progression was detected in 16.7&#x000a0;% in group B, no irradiated bone in group A showed a local progression over the course (<italic>p</italic> = 0.019). Progressive disease and systemic bone progression showed no difference between groups (<italic>p</italic> = 0.095 and <italic>p</italic> = 0.108; Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Tumor progression of both groups</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="2">Group A</th><th colspan="2">Group B</th><th/></tr><tr><th/><th>
<italic>n</italic>
</th><th>%</th><th>
<italic>n</italic>
</th><th>%</th><th>
<italic>P</italic>-value</th></tr></thead><tbody><tr><td>Progressive disease</td><td>22</td><td>73.3</td><td>27</td><td>90.0</td><td>0.095</td></tr><tr><td>Local bone progression</td><td>0</td><td>0.0</td><td>5</td><td>16.7</td><td>0.019</td></tr><tr><td>Systemic bone progression</td><td>8</td><td>26.7</td><td>14</td><td>46.7</td><td>0.108</td></tr></tbody></table></table-wrap></p><p>In univariate analysis breast cancer (HR 0.103, 95 % CI 0.024&#x02013;0.442, <italic>p</italic> = 0.002), prostate cancer (HR 0.160, 95 % CI 0.050&#x02013;0.511, <italic>p</italic>=0.002), and the presence of cerebral metastases (HR 3.211, 95 % CI 1.063&#x02013;9.695, <italic>p</italic> = 0.038) showed a significant impact on bone survival to group B, while no impact in group A could be demonstrated (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>).<table-wrap id="Tab3"><label>Table 3</label><caption><p>Univariate analysis for prognostic factors of bone survival</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th colspan="3">Intervention group (<italic>n</italic> = 30)</th><th colspan="3">Control group (<italic>n</italic> = 30)</th></tr><tr><th/><th>HR</th><th>CI 95&#x000a0;%</th><th>
<italic>P</italic>-value</th><th>HR</th><th>CI 95&#x000a0;%</th><th>
<italic>P</italic>-value</th></tr></thead><tbody><tr><td>Pathological fracture</td><td>1.288</td><td>0.371&#x02013;4.467</td><td>0.690</td><td>0.833</td><td>0.343&#x02013;2.020</td><td>0.686</td></tr><tr><td>KPS</td><td>0.527</td><td>0.216&#x02013;1.289</td><td>0.161</td><td>0.872</td><td>0.372&#x02013;2.043</td><td>0.752</td></tr><tr><td>Localization</td><td>0.588</td><td>0.209&#x02013;1.655</td><td>0.315</td><td>1.166</td><td>0.504&#x02013;2.694</td><td>0.720</td></tr><tr><td>Number of metastases</td><td>0.602</td><td>0.200&#x02013;1.812</td><td>0.366</td><td>1.052</td><td>0.469&#x02013;2.360</td><td>0.902</td></tr><tr><td>Breast cancer</td><td>0.230</td><td>0.028&#x02013;1.923</td><td>0.175</td><td>0.103</td><td>0.024&#x02013;0.442</td><td>0.002</td></tr><tr><td>NSCLC</td><td>2.442</td><td>0.834&#x02013;7.145</td><td>0.103</td><td>0.968</td><td>0.346&#x02013;2.712</td><td>0.951</td></tr><tr><td>Prostate cancer</td><td>0.950</td><td>0.237&#x02013;3.804</td><td>0.942</td><td>0.160</td><td>0.050&#x02013;0.511</td><td>0.002</td></tr><tr><td>Cerebral metastases</td><td>1.529</td><td>0.409&#x02013;5.716</td><td>0.528</td><td>3.211</td><td>1.063&#x02009;&#x02212;&#x02009;9.695</td><td>0.038</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec7" sec-type="discussion"><title>Discussion</title><p>The first results of this novel trial showed that guided resistance training of the paravertebral muscles can safely be practiced in palliative patients with stable bone metastases of the vertebral column. Furthermore improved pain and local response, reduced fatigue and enhanced QoL could be detected within 6&#x000a0;months.</p><p>In our current analysis, bone survival, overall survival, and PFS showed no significant differences between groups in long-term follow-up. The effect of resistance training showed an improved local response in group A [<xref ref-type="bibr" rid="CR16">16</xref>], and no local bone progression at the irradiated bone metastases could be detected, while in group B 16.7&#x000a0;% of patients expanded a progression in the vertebral body. Nevertheless these data had no impact on PFS. Overall survival and bone survival showed no differences as well. We interpreted this result as minor impact of resistance training. On the one hand, at baseline visceral metastases were significantly higher in group A, which represents a prognostic factor for survival in the literature, on the other hand a positive tendency for group A could be shown in overall survival and bone survival. Additional small sample size, and different primary tumor types played a major role on the assessment. The most prevalent tumors were those of breast and prostate [<xref ref-type="bibr" rid="CR21">21</xref>]. These tumor entities had an improved bone survival in group B, but showed no impact in group A. This result explained itself on account of several additional distant metastases which were detected in group A collectively. In a study by van der Linden et al. involving 342 patients with spinal metastases, the most important prognostic factors were performance status, metastatic involvement of other organs and primary site [<xref ref-type="bibr" rid="CR8">8</xref>]. In the study by Katagiri et al. [<xref ref-type="bibr" rid="CR22">22</xref>], primary tumor, performance status, number of bone metastases, metastatic involvement of other organs and previous chemotherapy regimens constituted important prognostic factors among 350 patients with bone metastases. In a retrospective analysis of 356 patients, Rades et al. [<xref ref-type="bibr" rid="CR23">23</xref>] identified that improved survival was significantly associated with female gender, an Eastern Cooperative Oncology Group performance score (ECOG-PS) of 1&#x02013;2, pre-RT ambulatory status, the absence of other bone metastases, the absence of visceral metastases, an interval from cancer diagnosis to RT of &#x0003e;15&#x000a0;months and slower (&#x0003e;7&#x000a0;days) development of motor deficits. Our trial was not able to demonstrate a survival benefit of resistance training concomitant to RT, and identified only tumor type and cerebral metastases as prognostic factors in our control group. However, the knowledge of prognostic factors and of the prognosis following bone metastasis is of critical importance. A paper by Sugiura et al. [<xref ref-type="bibr" rid="CR24">24</xref>] considering 118 patients with bone metastases showed a 1-year survival rate of 31.6&#x000a0;% and a 2-year survival rate of 11.3&#x000a0;% for lung cancer. Overall survival rates of patients with renal cell carcinoma were described with 74&#x000a0;% after one year [<xref ref-type="bibr" rid="CR25">25</xref>]. Correspondingly, the survival rates especially differ in the literature depending on the primary tumor. Based on the different primary types in our trial, these data are not comparable.</p><p>Bone metastases are among the most serious problems seen in tumor patients and bone pain, pathological fractures and neurological deficits can be life-threatening events [<xref ref-type="bibr" rid="CR26">26</xref>]. Palliative RT constitutes one of the most important therapeutic options in these situations. In our recent work, we were able to demonstrate a benefit in QoL, pain response, local response, and reduced fatigue for patients after combined treatment with resistance training concomitant to RT. However, our results showed no differences in survival. In our opinion, the combined treatment with resistance training concomitant to RT is a very effective novel treatment. Future trial designs should stratify to primary tumor and visceral metastases. Further limitations of the study were the relatively small sample size, the variety of primary tumors and patient conditions, and the exclusion of patients presenting with cervical spine metastases. Among the strengths of our novel and original study were the randomized design and long-term follow-up among palliative patients with spinal bone metastases.</p></sec><sec id="Sec8" sec-type="conclusion"><title>Conclusion</title><p>In this group of patients with spinal bone metastases we were able to show that guided resistance training of the paravertebral muscles had no essential impact on bone survival, overall survival, and progression free survival concomitant to RT. Importantly, the absence of local bone progression in group A could be detected, nevertheless no prognostic factor for combined treatment was evaluated.</p></sec></body><back><ack><title>Acknowledgements</title><p>This work was supported by a Heidelberg University young investigator grant to H. Rief. We thank our German Bone Cancer Research Group Members for their great effort. The authors thank all of the study participants for their participation.</p><sec id="FPar1"><title>Funding</title><p>Not applicable.</p></sec><sec id="FPar2"><title>Availability of data and materials</title><p>The data used in this analysis is from publications available in the public domain.</p></sec><sec id="FPar3"><title>Authors&#x02019;contributions</title><p>HR and JD developed and planned this trial. TB was responsible for statistical considerations/basis of the analysis. TW estimated the stability of bone metastases. HR, IS, TBo, and RF performed the examinations and RT supervisions. HR made the data collection and performed the resistance training. All authors read and approved the final manuscript.</p></sec><sec id="FPar4"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="FPar5"><title>Consent for publication</title><p>Not applicable.</p></sec><sec id="FPar6"><title>Ethics approval and consent to participate</title><p>The Heidelberg Ethics Committee approved this study on 1st August 2011 (S-316/2011).</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Coleman</surname><given-names>RE</given-names></name></person-group><article-title>Metastatic bone disease: Clinical features, pathophysiology and treatment strategies</article-title><source>Cancer Treat Rev</source><year>2001</year><volume>27</volume><fpage>165</fpage><lpage>176</lpage><pub-id pub-id-type="doi">10.1053/ctrv.2000.0210</pub-id><pub-id pub-id-type="pmid">11417967</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>B</given-names></name><name><surname>Mansfield</surname><given-names>FL</given-names></name><name><surname>Borges</surname><given-names>L</given-names></name></person-group><article-title>One-stage posterolateral decompression and stabilization for primary and metastatic vertebral tumors in the thoracic and lumbar spine</article-title><source>J Neurosurg</source><year>1989</year><volume>70</volume><fpage>405</fpage><lpage>410</lpage><pub-id pub-id-type="doi">10.3171/jns.1989.70.3.0405</pub-id><pub-id pub-id-type="pmid">2915247</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wyne</surname><given-names>CM</given-names></name><name><surname>Hu</surname><given-names>SS</given-names></name><name><surname>Lotz</surname><given-names>JC</given-names></name></person-group><article-title>Biomechanically derived guidline equations for burst fracture risk prediction in the metastatically involved spine</article-title><source>J Spin Disorders &#x00026; Techniques</source><year>2003</year><volume>16</volume><issue>2</issue><fpage>180</fpage><lpage>185</lpage><pub-id pub-id-type="doi">10.1097/00024720-200304000-00010</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janjan</surname><given-names>N</given-names></name><name><surname>Lutz</surname><given-names>ST</given-names></name><name><surname>Bedwinek</surname><given-names>JM</given-names></name><etal/></person-group><article-title>Therapeutic guidelines for the treatment of bone metastasis: a report from the American College of Radiology Appropriateness Criteria Expert Panel on Radiation Oncology</article-title><source>J Palliat Med</source><year>2009</year><volume>12</volume><fpage>417</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1089/jpm.2009.9633</pub-id><pub-id pub-id-type="pmid">19416037</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mitera</surname><given-names>G</given-names></name><name><surname>Probyn</surname><given-names>L</given-names></name><name><surname>Ford</surname><given-names>M</given-names></name><name><surname>Donovan</surname><given-names>A</given-names></name><name><surname>Rubenstein</surname><given-names>J</given-names></name><name><surname>Finkelstein</surname><given-names>J</given-names></name><name><surname>Christakis</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Campos</surname><given-names>S</given-names></name><name><surname>Culleton</surname><given-names>S</given-names></name><name><surname>Nguyen</surname><given-names>J</given-names></name><name><surname>Sahgal</surname><given-names>A</given-names></name><name><surname>Barnes</surname><given-names>E</given-names></name><name><surname>Tsao</surname><given-names>M</given-names></name><name><surname>Danjoux</surname><given-names>C</given-names></name><name><surname>Holden</surname><given-names>L</given-names></name><name><surname>Yee</surname><given-names>A</given-names></name><name><surname>Khan</surname><given-names>L</given-names></name><name><surname>Chow</surname><given-names>E</given-names></name></person-group><article-title>Correlation of computed tomography imaging features with pain response in patients with spine metastases after radiation therapy</article-title><source>Int J Radiation Oncol Biol Phys</source><year>2011</year><volume>81</volume><issue>3</issue><fpage>827</fpage><lpage>830</lpage><pub-id pub-id-type="doi">10.1016/j.ijrobp.2010.06.036</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>JS</given-names></name><name><surname>Monk</surname><given-names>G</given-names></name><name><surname>Clark</surname><given-names>T</given-names></name><name><surname>Robinson</surname><given-names>J</given-names></name><name><surname>Eigl</surname><given-names>BJ</given-names></name><name><surname>Hagen</surname><given-names>N</given-names></name></person-group><article-title>Palliative radiotherapy improves pain and reduces functional interference in patients with painful bone metastases: a quality assurance study</article-title><source>Clin Oncol</source><year>2006</year><volume>18</volume><fpage>539</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1016/j.clon.2006.05.003</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Oorschot</surname><given-names>B</given-names></name><name><surname>Schuler</surname><given-names>M</given-names></name><name><surname>Simon</surname><given-names>A</given-names></name><name><surname>Schleicher</surname><given-names>U</given-names></name><name><surname>Geinitz</surname><given-names>H</given-names></name></person-group><article-title>Patterns of care and course of symptoms in palliative radiotherapy: a multicenter pilot study analysis</article-title><source>Strahlenther Onkol</source><year>2011</year><volume>187</volume><issue>8</issue><fpage>461</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1007/s00066-011-2231-9</pub-id><pub-id pub-id-type="pmid">21786111</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van der Linden</surname><given-names>YM</given-names></name><name><surname>Dijkstra</surname><given-names>SP</given-names></name><name><surname>Vonk</surname><given-names>EJ</given-names></name><name><surname>Marijnen</surname><given-names>CA</given-names></name><name><surname>Leer</surname><given-names>JW</given-names></name></person-group><article-title>Prediction of survival in patients with metastases in the spinal column: results based on a randomized trial of radiotherapy</article-title><source>Cancer</source><year>2005</year><volume>103</volume><issue>2</issue><fpage>320</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1002/cncr.20756</pub-id><pub-id pub-id-type="pmid">15593360</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Klimo</surname><given-names>P</given-names><suffix>Jr</suffix></name><name><surname>Kestle</surname><given-names>JR</given-names></name><name><surname>Schmidt</surname><given-names>MH</given-names></name></person-group><article-title>Clinical trials and evidence-based medicine for metastatic spine disease</article-title><source>Neurosurg Clin N Am</source><year>2004</year><volume>15</volume><fpage>549</fpage><lpage>564</lpage><pub-id pub-id-type="doi">10.1016/j.nec.2004.04.016</pub-id><pub-id pub-id-type="pmid">15450889</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sioutos</surname><given-names>PJ</given-names></name><name><surname>Arbit</surname><given-names>E</given-names></name><name><surname>Meshulam</surname><given-names>CF</given-names></name><name><surname>Galicich</surname><given-names>JH</given-names></name></person-group><article-title>Spinal metastases from solid tumors. Analysis of factors affecting survival</article-title><source>Cancer</source><year>1995</year><volume>76</volume><issue>8</issue><fpage>1453</fpage><lpage>1459</lpage><pub-id pub-id-type="doi">10.1002/1097-0142(19951015)76:8&#x0003c;1453::AID-CNCR2820760824&#x0003e;3.0.CO;2-T</pub-id><pub-id pub-id-type="pmid">8620423</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>T</given-names></name><name><surname>Siemionow</surname><given-names>KB</given-names></name><name><surname>Mroz</surname><given-names>TE</given-names></name><name><surname>Podichetty</surname><given-names>V</given-names></name><name><surname>Lieberman</surname><given-names>IH</given-names></name></person-group><article-title>A prospective analysis of prognostic factors in patients with spinal metastases: use of the revised Tokuhashi score</article-title><source>Spine (Phila Pa 1976)</source><year>2011</year><volume>36</volume><issue>11</issue><fpage>910</fpage><lpage>917</lpage><pub-id pub-id-type="doi">10.1097/BRS.0b013e3181e56ec1</pub-id><pub-id pub-id-type="pmid">21037529</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foerster</surname><given-names>R</given-names></name><name><surname>Bruckner</surname><given-names>T</given-names></name><name><surname>Bostel</surname><given-names>T</given-names></name><name><surname>Schlampp</surname><given-names>I</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name><name><surname>Rief</surname><given-names>H</given-names></name></person-group><article-title>Prognostic factors for survival of women with unstable spinal bone metastases from breast cancer</article-title><source>Radiat Oncol</source><year>2015</year><volume>10</volume><fpage>144</fpage><pub-id pub-id-type="doi">10.1186/s13014-015-0458-9</pub-id><pub-id pub-id-type="pmid">26169373</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rief</surname><given-names>H</given-names></name><name><surname>Omlor</surname><given-names>G</given-names></name><name><surname>Akbar</surname><given-names>M</given-names></name><name><surname>Welzel</surname><given-names>T</given-names></name><name><surname>Bruckner</surname><given-names>T</given-names></name><name><surname>Rieken</surname><given-names>S</given-names></name><name><surname>Haefner</surname><given-names>MF</given-names></name><name><surname>Schlampp</surname><given-names>I</given-names></name><name><surname>Gioules</surname><given-names>A</given-names></name><name><surname>Habermehl</surname><given-names>D</given-names></name><name><surname>von Nettelbladt</surname><given-names>F</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name></person-group><article-title>Feasibility of isometric spinal muscle training in patients with bone metastases under radiation therapy - first results of a randomized pilot trial</article-title><source>BMC Cancer</source><year>2014</year><volume>14</volume><fpage>67</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-14-67</pub-id><pub-id pub-id-type="pmid">24499460</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rief</surname><given-names>H</given-names></name><name><surname>Akbar</surname><given-names>M</given-names></name><name><surname>Keller</surname><given-names>M</given-names></name><name><surname>Omlor</surname><given-names>G</given-names></name><name><surname>Welzel</surname><given-names>T</given-names></name><name><surname>Bruckner</surname><given-names>T</given-names></name><name><surname>Rieken</surname><given-names>S</given-names></name><name><surname>H&#x000e4;fner</surname><given-names>MF</given-names></name><name><surname>Schlampp</surname><given-names>I</given-names></name><name><surname>Gioules</surname><given-names>A</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name></person-group><article-title>Quality of life and fatigue of patients with spinal bone metastases under combined treatment with resistance training and radiation therapy- a randomized pilot trial</article-title><source>Radiat Oncol</source><year>2014</year><volume>9</volume><issue>1</issue><fpage>151</fpage><pub-id pub-id-type="doi">10.1186/1748-717X-9-151</pub-id><pub-id pub-id-type="pmid">24998293</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rief</surname><given-names>H</given-names></name><name><surname>Welzel</surname><given-names>T</given-names></name><name><surname>Omlor</surname><given-names>G</given-names></name><name><surname>Akbar</surname><given-names>M</given-names></name><name><surname>Bruckner</surname><given-names>T</given-names></name><name><surname>Rieken</surname><given-names>S</given-names></name><name><surname>Haefner</surname><given-names>MF</given-names></name><name><surname>Schlampp</surname><given-names>I</given-names></name><name><surname>Gioules</surname><given-names>A</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name></person-group><article-title>Pain response of resistance training of the paravertebral musculature under radiotherapy in patients with spinal bone metastases-a randomized trial</article-title><source>BMC Cancer</source><year>2014</year><volume>14</volume><fpage>485</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-14-485</pub-id><pub-id pub-id-type="pmid">24996223</pub-id></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rief</surname><given-names>H</given-names></name><name><surname>Petersen</surname><given-names>LC</given-names></name><name><surname>Omlor</surname><given-names>G</given-names></name><name><surname>Akbar</surname><given-names>M</given-names></name><name><surname>Bruckner</surname><given-names>T</given-names></name><name><surname>Rieken</surname><given-names>S</given-names></name><name><surname>Haefner</surname><given-names>MF</given-names></name><name><surname>Schlampp</surname><given-names>I</given-names></name><name><surname>F&#x000f6;rster</surname><given-names>R</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name></person-group><article-title>Welzel T; German Bone Research Group. The effect of resistance training during radiotherapy on spinal bone metastases in cancer patients - A randomized trial</article-title><source>Radiother Oncol</source><year>2014</year><volume>112</volume><issue>1</issue><fpage>133</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.radonc.2014.06.008</pub-id><pub-id pub-id-type="pmid">25012645</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><mixed-citation publication-type="other">Karnofsky DA, Burchenal JH. The Clinical Evaluation of Chemotherapeutic Agents in Cancer. In: MacLeod CM, editors. Evaluation of Chemotherapeutic Agents. New York; 1949. p. 191&#x02013;205.</mixed-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taneichi</surname><given-names>H</given-names></name><name><surname>Kaneda</surname><given-names>K</given-names></name><name><surname>Takeda</surname><given-names>N</given-names></name><name><surname>Abumi</surname><given-names>K</given-names></name><name><surname>Satoh</surname><given-names>S</given-names></name></person-group><article-title>Risk factors and probability of vertebral body collapse in metastases of the thoracic and lumbar spine</article-title><source>Spine</source><year>1997</year><volume>22</volume><fpage>239</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1097/00007632-199702010-00002</pub-id><pub-id pub-id-type="pmid">9051884</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hamaoka</surname><given-names>T</given-names></name><name><surname>Costelloe</surname><given-names>CM</given-names></name><name><surname>Madewell</surname><given-names>JE</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name><name><surname>Berry</surname><given-names>DA</given-names></name><name><surname>Islam</surname><given-names>R</given-names></name><name><surname>Theriault</surname><given-names>RL</given-names></name><name><surname>Hortobagyi</surname><given-names>GN</given-names></name><name><surname>Ueno</surname><given-names>NT</given-names></name></person-group><article-title>Tumour response interpretation with new tumour response criteria vs the World Health Organisation criteria in patients with bone-only metastatic breast cancer</article-title><source>Br J Cancer</source><year>2010</year><volume>102</volume><issue>4</issue><fpage>651</fpage><lpage>657</lpage><pub-id pub-id-type="doi">10.1038/sj.bjc.6605546</pub-id><pub-id pub-id-type="pmid">20104228</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rief</surname><given-names>H</given-names></name><name><surname>Jensen</surname><given-names>AD</given-names></name><name><surname>Bruckner</surname><given-names>T</given-names></name><name><surname>Herfarth</surname><given-names>K</given-names></name><name><surname>Debus</surname><given-names>J</given-names></name></person-group><article-title>Isometric muscle training of the spine musculature in patients with spinal bony metastases under radiation therapy</article-title><source>BMC Cancer</source><year>2011</year><volume>11</volume><fpage>482</fpage><pub-id pub-id-type="doi">10.1186/1471-2407-11-482</pub-id><pub-id pub-id-type="pmid">22070722</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bollen</surname><given-names>L</given-names></name><name><surname>van der Linden</surname><given-names>YM</given-names></name><name><surname>Pondaag</surname><given-names>W</given-names></name><name><surname>Fiocco</surname><given-names>M</given-names></name><name><surname>Pattynama</surname><given-names>BP</given-names></name><name><surname>Marijnen</surname><given-names>CA</given-names></name><name><surname>Nelissen</surname><given-names>RG</given-names></name><name><surname>Peul</surname><given-names>WC</given-names></name><name><surname>Dijkstra</surname><given-names>PD</given-names></name></person-group><article-title>Prognostic factors associated with survival in patients with symptomatic spinal bone metastases: a retrospective cohort study of 1,043 patients</article-title><source>Neuro Oncol</source><year>2014</year><volume>16</volume><issue>7</issue><fpage>991</fpage><lpage>998</lpage><pub-id pub-id-type="doi">10.1093/neuonc/not318</pub-id><pub-id pub-id-type="pmid">24470544</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Katagiri</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Wakai</surname><given-names>K</given-names></name><name><surname>Sugiura</surname><given-names>H</given-names></name><name><surname>Kataoka</surname><given-names>T</given-names></name><name><surname>Nakanishi</surname><given-names>K</given-names></name></person-group><article-title>Prognostic factors and a scoring system for patients with skleletal metastasis</article-title><source>J Bone Joint Surg (Br)</source><year>2005</year><volume>87</volume><fpage>698</fpage><lpage>703</lpage><pub-id pub-id-type="doi">10.1302/0301-620X.87B5.15185</pub-id><pub-id pub-id-type="pmid">15855375</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rades</surname><given-names>D</given-names></name><name><surname>Douglas</surname><given-names>S</given-names></name><name><surname>Veninga</surname><given-names>T</given-names></name><name><surname>Bajrovic</surname><given-names>A</given-names></name><name><surname>Stalpers</surname><given-names>LJ</given-names></name><name><surname>Hoskin</surname><given-names>PJ</given-names></name><name><surname>Rudat</surname><given-names>V</given-names></name><name><surname>Schild</surname><given-names>SE</given-names></name></person-group><article-title>Metastatic spinal cord compression in non-small cell lung cancer patients. Prognostic factors in a series of 356 patients</article-title><source>Strahlenther Onkol</source><year>2012</year><volume>188</volume><fpage>472</fpage><lpage>476</lpage><pub-id pub-id-type="doi">10.1007/s00066-012-0086-3</pub-id><pub-id pub-id-type="pmid">22361746</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sugiura</surname><given-names>H</given-names></name><name><surname>Yamada</surname><given-names>K</given-names></name><name><surname>Sugiura</surname><given-names>T</given-names></name><name><surname>Hida</surname><given-names>T</given-names></name><name><surname>Mitsudomi</surname><given-names>T</given-names></name></person-group><article-title>Predictors of survival in patients with bone metastasis of lung cancer</article-title><source>Clin Orthop Relat Res</source><year>2008</year><volume>466</volume><issue>3</issue><fpage>729</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1007/s11999-007-0051-0</pub-id><pub-id pub-id-type="pmid">18196360</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Ma</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Shao</surname><given-names>K</given-names></name><name><surname>Zhu</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name></person-group><article-title>Can Urol Assoc J. Prognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma</article-title><source>Can Urol Assoc J</source><year>2014</year><volume>8</volume><issue>11&#x02013;12</issue><fpage>E821</fpage><lpage>E827</lpage><pub-id pub-id-type="pmid">25485010</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuya</surname><given-names>A</given-names></name><name><surname>Kurata</surname><given-names>T</given-names></name><name><surname>Tamura</surname><given-names>K</given-names></name><name><surname>Fukuoka</surname><given-names>M</given-names></name></person-group><article-title>Skeletal metastases in non-small cell lung cancer: a retrospective study</article-title><source>Lung Cancer</source><year>2007</year><volume>57</volume><fpage>229</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/j.lungcan.2007.03.013</pub-id><pub-id pub-id-type="pmid">17451841</pub-id></element-citation></ref></ref-list></back></article>